# Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors

> **NCT01118611** · PHASE1 · COMPLETED · sponsor: **Cancer Research UK** · enrollment: 38 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** Aurora B/C kinase inhibitor GSK1070916A
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** diffusion-weighted magnetic resonance imaging + PET CT
- **RADIATION:** fludeoxyglucose F 18 dynomic contrast

## Key facts

- **NCT ID:** NCT01118611
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118611, "Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01118611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*